CHRS
Price
$1.03
Change
+$0.03 (+3.00%)
Updated
Apr 30 closing price
Capitalization
115.85M
7 days until earnings call
SPRO
Price
$0.66
Change
-$0.01 (-1.49%)
Updated
Apr 30 closing price
Capitalization
36.06M
8 days until earnings call
Ad is loading...

CHRS vs SPRO

Header iconCHRS vs SPRO Comparison
Open Charts CHRS vs SPROBanner chart's image
Coherus BioSciences
Price$1.03
Change+$0.03 (+3.00%)
Volume$1.83M
Capitalization115.85M
Spero Therapeutics
Price$0.66
Change-$0.01 (-1.49%)
Volume$79.29K
Capitalization36.06M
CHRS vs SPRO Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. SPRO commentary
May 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and SPRO is a Buy.

Ad is loading...
COMPARISON
Comparison
May 01, 2025
Stock price -- (CHRS: $1.02 vs. SPRO: $0.64)
Brand notoriety: CHRS and SPRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 96% vs. SPRO: 57%
Market capitalization -- CHRS: $115.85M vs. SPRO: $36.06M
CHRS [@Biotechnology] is valued at $115.85M. SPRO’s [@Biotechnology] market capitalization is $36.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $279.46B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileSPRO’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • SPRO’s FA Score: 1 green, 4 red.
According to our system of comparison, SPRO is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while SPRO’s TA Score has 5 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 5 bearish.
  • SPRO’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SPRO is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а -7.66% price change this week, while SPRO (@Biotechnology) price change was -11.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.45%. For the same industry, the average monthly price growth was +5.12%, and the average quarterly price growth was -6.68%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

SPRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+4.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($116M) has a higher market cap than SPRO($36.1M). SPRO has higher P/E ratio than CHRS: SPRO (10.75) vs CHRS (4.00). CHRS YTD gains are higher at: -25.725 vs. SPRO (-37.379). CHRS has higher annual earnings (EBITDA): 37.3M vs. SPRO (-2.45M). CHRS has more cash in the bank: 97.7M vs. SPRO (76.3M). SPRO has less debt than CHRS: SPRO (4.62M) vs CHRS (270M). CHRS has higher revenues than SPRO: CHRS (304M) vs SPRO (89.9M).
CHRSSPROCHRS / SPRO
Capitalization116M36.1M321%
EBITDA37.3M-2.45M-1,524%
Gain YTD-25.725-37.37969%
P/E Ratio4.0010.7537%
Revenue304M89.9M338%
Total Cash97.7M76.3M128%
Total Debt270M4.62M5,842%
FUNDAMENTALS RATINGS
CHRS vs SPRO: Fundamental Ratings
CHRS
SPRO
OUTLOOK RATING
1..100
2514
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10066
PRICE GROWTH RATING
1..100
4989
P/E GROWTH RATING
1..100
535
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPRO's Valuation (48) in the Pharmaceuticals Major industry is somewhat better than the same rating for CHRS (91) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CHRS’s over the last 12 months.

SPRO's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CHRS (100) in the Biotechnology industry. This means that SPRO’s stock grew similarly to CHRS’s over the last 12 months.

SPRO's SMR Rating (66) in the Pharmaceuticals Major industry is somewhat better than the same rating for CHRS (100) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CHRS’s over the last 12 months.

CHRS's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for SPRO (89) in the Pharmaceuticals Major industry. This means that CHRS’s stock grew somewhat faster than SPRO’s over the last 12 months.

SPRO's P/E Growth Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for CHRS (53) in the Biotechnology industry. This means that SPRO’s stock grew somewhat faster than CHRS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CHRSSPRO
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
72%
Bullish Trend 16 days ago
72%
Declines
ODDS (%)
Bearish Trend 27 days ago
86%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
N/A
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IQV155.071.62
+1.06%
IQVIA Holdings
UONE1.50N/A
N/A
Urban One
BLBD34.87-0.49
-1.37%
Blue Bird Corp
DOCS56.88-0.87
-1.51%
Doximity
COMM3.74-0.14
-3.61%
CommScope Holding Company

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with ADCT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then ADCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+2.54%
ADCT - CHRS
39%
Loosely correlated
+0.70%
ARRY - CHRS
39%
Loosely correlated
-9.64%
AXON - CHRS
38%
Loosely correlated
+0.33%
XENE - CHRS
36%
Loosely correlated
-0.55%
AMRN - CHRS
35%
Loosely correlated
+4.16%
More